Valuation: Viatris Inc.

Market Cap 20.22B 18.03B 16.8B 15.29B 28.79B 1,947B 29.01B 203B 78.98B 994B 75.89B 74.25B 3,194B P/E 2026 *
75.7x
P/E 2027 * 43.3x
Enterprise Value 32.17B 28.7B 26.73B 24.33B 45.82B 3,098B 46.16B 323B 126B 1,581B 121B 118B 5,082B EV / Sales 2026 *
2.18x
EV / Sales 2027 * 2.05x
Free-Float
91.44%
Yield 2026 *
2.89%
Yield 2027 * 2.97%
1 day+1.58%
1 week+2.58%
Current month-1.45%
1 month+7.41%
3 months+8.97%
6 months+34.22%
Current year+49.18%
1 week 15.46
Extreme 15.456
16.14
1 month 13.93
Extreme 13.932
16.14
Current year 10.49
Extreme 10.49
16.14
1 year 8.4
Extreme 8.404
16.14
3 years 6.26
Extreme 6.262
16.14
5 years 6.26
Extreme 6.262
16.14
10 years 6.26
Extreme 6.262
16.14
Manager TitleAgeSince
Chief Executive Officer 63 01/04/2023
Director of Finance/CFO 59 08/05/2026
Chief Tech/Sci/R&D Officer - 15/12/2023
Director TitleAgeSince
Director/Board Member 78 16/11/2020
Director/Board Member 78 16/11/2020
Director/Board Member 62 16/11/2020
Change 5-day change 1-year change 3-year change Capi.($)
+1.58%+2.58% - - 20.22B
+0.02%-3.52%+35.27%+111.11% 1,019B
-1.21%-6.99%+34.42%+60.96% 617B
+1.12%-0.20%+15.45%+80.24% 464B
-3.30%-6.15%+57.14%+34.69% 356B
+0.93%-3.16%+21.65%+43.02% 333B
+0.12%-2.77%+10.70%+32.97% 267B
-0.89%-6.28%-7.00%+8.01% 244B
-0.01%-3.62%+37.01%+52.02% 218B
-0.08%-4.98%+27.34%+93.61% 179B
Average -0.48%-3.54%+25.78%+57.40% 410.8B
Weighted average by Cap. -0.46%-3.54%+28.68%+68.60%

Financials

2026 *2027 *
Net sales 14.79B 13.19B 12.29B 11.19B 21.06B 1,424B 21.22B 149B 57.78B 727B 55.52B 54.32B 2,337B 15.04B 13.41B 12.5B 11.37B 21.42B 1,448B 21.58B 151B 58.75B 739B 56.45B 55.23B 2,376B
Net income 142M 126M 118M 107M 202M 13.63B 203M 1.42B 553M 6.96B 531M 520M 22.36B 298M 266M 248M 226M 425M 28.74B 428M 3B 1.17B 14.67B 1.12B 1.1B 47.15B
Net Debt 11.95B 10.66B 9.93B 9.04B 17.02B 1,151B 17.15B 120B 46.69B 587B 44.86B 43.9B 1,888B 10.68B 9.53B 8.88B 8.08B 15.22B 1,029B 15.33B 107B 41.75B 525B 40.11B 39.24B 1,688B
Logo Viatris Inc.
Viatris Inc. is a global healthcare company. The Company markets branded and generic drugs, including complex drugs. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Company's Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The Company's JANZ segment consists of its operations in Japan, Australia and New Zealand. Its Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. It produces medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, it offers treatment options across more than 10 major therapeutic areas covering a variety of noncommunicable and infectious diseases.
Employees
30,000
Date Price Change Volume
05/10/26 EUR 15.66 +1.35% 0
02/10/26 EUR 15.46 -1.63% 0
01/10/26 EUR 15.71 -1.15% 0
30/09/26 EUR 15.89 -0.95% 0
29/09/26 EUR 16.05 +2.36% 0
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
17.60USD
Average target price
19.40USD
Spread / Average Target
+10.23%

Quarterly revenue - Rate of surprise